首页 > 最新文献

Nephrologie & Therapeutique最新文献

英文 中文
Prediction of sarcopenia among peritoneal dialysis patients using a combination of irisin and phase angle 鸢尾素和相位角联合应用预测腹膜透析患者肌肉减少症
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-03-16 DOI: 10.1684/ndt.2023.7
Jiaying Wu, Jichao Guan, Shuangxiang Lin, Xiujuan Wu, Miaojia Ding, Zhouhao Ren, Shuijuan Shen

Background: Sarcopenia is associated with significant morbidity and mortality in patients undergoing peritoneal dialysis (PD). Three different tools must be applied to measure the three indices for diagnosing sarcopenia. Considering the cumbersome diagnostic steps and multi-layered mechanisms underlying sarcopenia, we combined new biomarker with bioelectrical impedance analysis (BIA) data to predict PD sarcopenia.

Methods: Patients underwent regular PD were asked to complete sarcopenia screening, including appendicular skeletal muscle mass, handgrip strength, and the 5-time chair stand time test according to the newly revised diagnosis consensus of Asian Working Group for Sarcopenia (AWGS2019). Serum was collected for centralized detection of the irisin levels. BIA data, especially the phase angle (PhA), as well as patient's general clinical information, dialysis related indices, laboratory data and body composition data were recorded.

Results: Among 105 enrolled PD patients (41.0% men, mean age 54.2 ± 8.89 years), the sarcopenia prevalence was 31.4% and the sarcopenic obesity was 8.6%. Binary regression analysis showed that serum irisin concentrations (OR = 0.98; 95% CI,0.97-0.99; p = 0.002), PhA (OR = 0.43; 95% CI, 0.21-0.90; p = 0.025) and body mass index (BMI) (OR = 0.64; 95% CI, 0.49-0.83; p = 0.001) were independently associated with PD sarcopenia. The AUC of the combination use of serum irisin concentrations and PhA for predicting PD sarcopenia was 0.925 with a sensitivity of 100% and specificity of 84.0% in male and was 0.880 with a sensitivity of 92.0% and specificity of 81.5% in female. PD sarcopenia score=1533.48+-0.75*Handgrip strength+4.63*BMI+-18.07*Total body water +-11.87*Extra-cellular water / total body water +9.26*Fat free mass index+-83.41*PhA+22.42*Albumin/Globulin+-26.38*blood phosphorus+-17.04*Total cholesterol+-29.02*Triglyceride+-0.29*Prealbumin+-0.17*Irisin.

Conclusions: Sarcopenia is relatively common among PD patients. The combination of serum irisin concentrations and PhA facilitated the rapid prediction of PD sarcopenia and could serve as an optimal screening tool for PD sarcopenia in clinical settings.

背景:腹膜透析(PD)患者的肌肉减少症与显著的发病率和死亡率相关。三种不同的工具必须用于测量三个指标诊断肌少症。考虑到肌少症的繁琐诊断步骤和多层机制,我们将新的生物标志物与生物电阻抗分析(BIA)数据结合起来预测PD肌少症。方法:根据亚洲肌肉减少症工作组(AWGS2019)新修订的诊断共识,要求常规PD患者完成肌肉减少症筛查,包括阑尾骨骼肌质量、握力和5次椅子站立时间测试。收集血清集中检测鸢尾素水平。记录BIA数据,特别是相位角(PhA),以及患者一般临床资料、透析相关指标、实验室数据和体成分数据。结果:105例PD患者(男性41.0%,平均年龄54.2±8.89岁)中,肌少症患病率为31.4%,肌少性肥胖患病率为8.6%。二元回归分析显示,血清鸢尾素浓度(OR = 0.98;95%置信区间,0.97 - -0.99;p = 0.002), PhA (OR = 0.43;95% ci, 0.21-0.90;p = 0.025)和身体质量指数(BMI) (OR = 0.64;95% ci, 0.49-0.83;p = 0.001)与PD肌少症独立相关。血清鸢尾素浓度与PhA联合预测PD肌少症的AUC男性为0.925,敏感性为100%,特异性为84.0%;女性为0.880,敏感性为92.0%,特异性为81.5%。PD肌少症评分=1533.48+-0.75*握力+4.63*BMI+-18.07*全身水分+-11.87*细胞外水分/全身水分+9.26*无脂质量指数+-83.41*PhA+22.42*白蛋白/球蛋白+-26.38*血磷+-17.04*总胆固醇+-29.02*甘油三酯+-0.29*白蛋白前蛋白+-0.17*鸢尾素。结论:肌少症在PD患者中较为常见。血清鸢尾素浓度与PhA的结合有助于PD肌少症的快速预测,可作为临床PD肌少症的最佳筛查工具。
{"title":"Prediction of sarcopenia among peritoneal dialysis patients using a combination of irisin and phase angle","authors":"Jiaying Wu,&nbsp;Jichao Guan,&nbsp;Shuangxiang Lin,&nbsp;Xiujuan Wu,&nbsp;Miaojia Ding,&nbsp;Zhouhao Ren,&nbsp;Shuijuan Shen","doi":"10.1684/ndt.2023.7","DOIUrl":"https://doi.org/10.1684/ndt.2023.7","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia is associated with significant morbidity and mortality in patients undergoing peritoneal dialysis (PD). Three different tools must be applied to measure the three indices for diagnosing sarcopenia. Considering the cumbersome diagnostic steps and multi-layered mechanisms underlying sarcopenia, we combined new biomarker with bioelectrical impedance analysis (BIA) data to predict PD sarcopenia.</p><p><strong>Methods: </strong>Patients underwent regular PD were asked to complete sarcopenia screening, including appendicular skeletal muscle mass, handgrip strength, and the 5-time chair stand time test according to the newly revised diagnosis consensus of Asian Working Group for Sarcopenia (AWGS2019). Serum was collected for centralized detection of the irisin levels. BIA data, especially the phase angle (PhA), as well as patient's general clinical information, dialysis related indices, laboratory data and body composition data were recorded.</p><p><strong>Results: </strong>Among 105 enrolled PD patients (41.0% men, mean age 54.2 ± 8.89 years), the sarcopenia prevalence was 31.4% and the sarcopenic obesity was 8.6%. Binary regression analysis showed that serum irisin concentrations (OR = 0.98; 95% CI,0.97-0.99; p = 0.002), PhA (OR = 0.43; 95% CI, 0.21-0.90; p = 0.025) and body mass index (BMI) (OR = 0.64; 95% CI, 0.49-0.83; p = 0.001) were independently associated with PD sarcopenia. The AUC of the combination use of serum irisin concentrations and PhA for predicting PD sarcopenia was 0.925 with a sensitivity of 100% and specificity of 84.0% in male and was 0.880 with a sensitivity of 92.0% and specificity of 81.5% in female. PD sarcopenia score=1533.48+-0.75*Handgrip strength+4.63*BMI+-18.07*Total body water +-11.87*Extra-cellular water / total body water +9.26*Fat free mass index+-83.41*PhA+22.42*Albumin/Globulin+-26.38*blood phosphorus+-17.04*Total cholesterol+-29.02*Triglyceride+-0.29*Prealbumin+-0.17*Irisin.</p><p><strong>Conclusions: </strong>Sarcopenia is relatively common among PD patients. The combination of serum irisin concentrations and PhA facilitated the rapid prediction of PD sarcopenia and could serve as an optimal screening tool for PD sarcopenia in clinical settings.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"66-75"},"PeriodicalIF":0.7,"publicationDate":"2023-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9517567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pregnancy after kidney transplantation: Ibn Sina Rabat University hospital experience 肾移植后妊娠:伊本西那拉巴特大学医院经验
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-03-15 DOI: 10.1684/ndt.2023.2
Latifa Driouch, Asmaa Azzouzi, Naima Ouzeddoun, Loubna Benamar, Rabia Bayahia, Tarik Bouattar

Introduction: Kidney transplantation (KT) restores the fertility of women with end-stage kidney disease (ESKD), thus offering them the possibility of having children. However, pregnancy after kidney transplantation is associated with high maternal-fetal morbidity. The purpose of this work is to report the experience of our service in pregnancies in kidney transplant recipients.

Materials and methods: We retrospectively studied the records of transplant recipients who had one or more pregnancies after KT. We analyzed clinical (blood pressure, weight gain, oedema, duration of pregnancy, obstetric complication) and biological (creatinine, urinary albumin excretion) parameters.

Results: Between 1998 and 2020, twenty-one pregnancies occurred in 12 transplant recipients. The average age of patients at the time of conception was 29 ± 5 years with a delay between KT and pregnancy of 43 ± 29 months. Seven pregnancies began with arterial hypertension (HTA) controlled under treatment, proteinuria before conception was negative in all pregnancies and renal function was normal with an average creatinine level of 10.1 ± 1,27 mg/L. Prior to pregnancy, immunosuppression regimens were based on anticalcineurin (n = 21) combined either with mycophenolate mofetil (MMF) (n = 10) or azathioprine (n = 8) or alone (n = 3). Immunosuppression regimens were all associated with corticosteroid therapy. Three months before conception, MMF was relayed by azathioprine in seven pregnancies, on the other hand three other unplanned pregnancies, started under MMF. During pregnancy, the appearance of proteinuria greater than 0,5 g/24 h was noted in three pregnancies in the third trimester. Pregnancy hypertension was found in three pregnancies, one of which progressed to pre-eclampsia. As for renal function, it remained stable with an average creatinine level of 10,3 mg/l in the 3rd trimester. Two cases of acute pyelonephritis were noted. No episode of acute rejection was noted during and 3 months after pregnancy. The delivery was performed by caesarean section in 44.4 %, after an average term of 37 week of amenorrhea ± 2.04 with three cases of prematurity. The average birth weight was 3 110 g ± 450 g. There was one case of spontaneous abortion and two cases of fetal death in utero. After post-partum, renal function remained stable in five patients. In six cases, there was impaired renal function either by acute rejection or secondary to chronic allograft nephropathy.

Conclusion: In our department, a quarter of transplant recipients were able to carry a pregnancy with a rate of 89 % of successful pregnancies. Pregnancy after KT requires special planning and monitoring. A multidisciplinary collaboration between transplant nephrologist, gynecologist and pediatrician is necessary by referring to the recommendations.

肾移植(KT)恢复终末期肾病(ESKD)妇女的生育能力,从而为她们提供生育的可能性。然而,肾移植后妊娠与高母胎发病率相关。这项工作的目的是报告我们的服务经验,怀孕的肾移植受者。材料和方法:我们回顾性研究了移植受者在KT后一次或多次怀孕的记录。我们分析了临床(血压、体重增加、水肿、妊娠持续时间、产科并发症)和生物学(肌酐、尿白蛋白排泄)参数。结果:1998年至2020年间,12例移植受者发生21例妊娠。患者平均受孕年龄为29±5岁,KT至妊娠延迟43±29个月。7例妊娠开始时动脉高血压(HTA)在治疗控制下,妊娠前蛋白尿均为阴性,肾功能正常,平均肌酐水平为10.1±1.27 mg/L。在怀孕前,免疫抑制方案基于抗钙化神经磷酸酶(n = 21)联合霉酚酸酯(MMF) (n = 10)或硫唑嘌呤(n = 8)或单独(n = 3)。免疫抑制方案均与皮质类固醇治疗相关。在怀孕前3个月,MMF在7次怀孕中被硫唑嘌呤传递,另一方面,另外3次意外怀孕在MMF下开始。妊娠期间,有3例妊娠晚期出现大于0.5 g/24 h的蛋白尿。妊娠高血压发现在三个怀孕,其中一个进展到先兆子痫。肾功能保持稳定,妊娠晚期平均肌酐水平为10.3 mg/l。报告急性肾盂肾炎2例。妊娠期间和妊娠后3个月未发生急性排斥反应。术后平均37周闭经±2.04周,早产3例,剖宫产率44.4%。平均出生体重为3 110 g±450 g。1例自然流产,2例宫内胎儿死亡。5例患者产后肾功能保持稳定。在6例中,急性排斥反应或继发于慢性同种异体移植肾病导致肾功能受损。结论:在我科,1 / 4的移植受者能够顺利妊娠,成功妊娠率为89%。KT后怀孕需要特别的计划和监控。参考这些建议,移植肾病专家、妇科医生和儿科医生之间的多学科合作是必要的。
{"title":"Pregnancy after kidney transplantation: Ibn Sina Rabat University hospital experience","authors":"Latifa Driouch,&nbsp;Asmaa Azzouzi,&nbsp;Naima Ouzeddoun,&nbsp;Loubna Benamar,&nbsp;Rabia Bayahia,&nbsp;Tarik Bouattar","doi":"10.1684/ndt.2023.2","DOIUrl":"https://doi.org/10.1684/ndt.2023.2","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney transplantation (KT) restores the fertility of women with end-stage kidney disease (ESKD), thus offering them the possibility of having children. However, pregnancy after kidney transplantation is associated with high maternal-fetal morbidity. The purpose of this work is to report the experience of our service in pregnancies in kidney transplant recipients.</p><p><strong>Materials and methods: </strong>We retrospectively studied the records of transplant recipients who had one or more pregnancies after KT. We analyzed clinical (blood pressure, weight gain, oedema, duration of pregnancy, obstetric complication) and biological (creatinine, urinary albumin excretion) parameters.</p><p><strong>Results: </strong>Between 1998 and 2020, twenty-one pregnancies occurred in 12 transplant recipients. The average age of patients at the time of conception was 29 ± 5 years with a delay between KT and pregnancy of 43 ± 29 months. Seven pregnancies began with arterial hypertension (HTA) controlled under treatment, proteinuria before conception was negative in all pregnancies and renal function was normal with an average creatinine level of 10.1 ± 1,27 mg/L. Prior to pregnancy, immunosuppression regimens were based on anticalcineurin (n = 21) combined either with mycophenolate mofetil (MMF) (n = 10) or azathioprine (n = 8) or alone (n = 3). Immunosuppression regimens were all associated with corticosteroid therapy. Three months before conception, MMF was relayed by azathioprine in seven pregnancies, on the other hand three other unplanned pregnancies, started under MMF. During pregnancy, the appearance of proteinuria greater than 0,5 g/24 h was noted in three pregnancies in the third trimester. Pregnancy hypertension was found in three pregnancies, one of which progressed to pre-eclampsia. As for renal function, it remained stable with an average creatinine level of 10,3 mg/l in the 3rd trimester. Two cases of acute pyelonephritis were noted. No episode of acute rejection was noted during and 3 months after pregnancy. The delivery was performed by caesarean section in 44.4 %, after an average term of 37 week of amenorrhea ± 2.04 with three cases of prematurity. The average birth weight was 3 110 g ± 450 g. There was one case of spontaneous abortion and two cases of fetal death in utero. After post-partum, renal function remained stable in five patients. In six cases, there was impaired renal function either by acute rejection or secondary to chronic allograft nephropathy.</p><p><strong>Conclusion: </strong>In our department, a quarter of transplant recipients were able to carry a pregnancy with a rate of 89 % of successful pregnancies. Pregnancy after KT requires special planning and monitoring. A multidisciplinary collaboration between transplant nephrologist, gynecologist and pediatrician is necessary by referring to the recommendations.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-11"},"PeriodicalIF":0.7,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9517566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
New developments and future prospects in the field of glomerular filtration rate estimation 肾小球滤过率测定领域的新进展及展望
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-03-02 DOI: 10.1684/ndt.2023.11
Thomas Stehlé, Emmanuelle Vidal-Petiot, Martin Flamant, Pierre Delanaye

Glomerular filtration rate (GFR) is estimated from equations based on serum or plasma concentrations of endogenous markers (creatinine and/or cystatin C), and demographic data (age, sex, ± ethnicity). These equations are accurate at the population level, but often inaccurate at the individual level. The creatinine-based Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation published in 2009 (CKD-EPIcr-2009), and the CKD-EPI equation published in 2012 based on creatinine and cystatin C, were recalibrated in 2021 to remove their dedicated race correction factors for black American subjects. All creatinine-based CKD-EPI equations overestimate true GFR in subjects younger than 30 years. The Full Age Spectrum (FAS) equation, applicable across the entire age spectrum (pediatrics to old age), solved this problem, but remained suboptimal at low GFR values. The European Kidney Function Consortium (EKFC) equation published in 2021 was an improvement of the FAS equation, which also includes the Q factor (median creatinine in the general population). EKFC is applicable across the age spectrum and is efficient at low and normal GFR values. The new creatinine-based CKD-EPI equation (CKD-EPIcr-2021) underestimates GFR in Black Americans and overestimates it in non-Black Americans. In European and African subjects, CKD-EPIcr-2021 overestimates true GFR and should not be adopted. The EKFC equation, which performs well in this population, also performs well in European Black subjects and in African subjects, provided dedicated Q factors are used.

肾小球滤过率(GFR)是根据血清或血浆内源性标志物(肌酐和/或胱抑素C)浓度和人口统计学数据(年龄、性别、±种族)的方程来估计的。这些方程在总体水平上是准确的,但在个人水平上往往是不准确的。2009年发布的基于肌酐的慢性肾脏疾病流行病学合作(CKD-EPI)方程(CKD-EPIcr-2009)和2012年发布的基于肌酐和胱抑制素C的CKD-EPI方程在2021年重新校准,以消除其针对美国黑人受试者的专门种族校正因素。所有基于肌酐的CKD-EPI方程都高估了30岁以下受试者的真实GFR。全年龄谱(FAS)方程,适用于整个年龄谱(儿科到老年),解决了这个问题,但在低GFR值时仍然不是最佳的。2021年发布的欧洲肾功能联盟(EKFC)方程是对FAS方程的改进,FAS方程还包括Q因子(一般人群中位数肌酐)。EKFC适用于整个年龄谱,在低和正常GFR值时有效。新的基于肌酐的CKD-EPI方程(CKD-EPIcr-2021)低估了美国黑人的GFR,高估了非黑人美国人的GFR。在欧洲和非洲受试者中,CKD-EPIcr-2021高估了真实GFR,不应采用。如果使用专门的Q因子,EKFC方程在这一人群中表现良好,在欧洲黑人受试者和非洲受试者中也表现良好。
{"title":"New developments and future prospects in the field of glomerular filtration rate estimation","authors":"Thomas Stehlé,&nbsp;Emmanuelle Vidal-Petiot,&nbsp;Martin Flamant,&nbsp;Pierre Delanaye","doi":"10.1684/ndt.2023.11","DOIUrl":"https://doi.org/10.1684/ndt.2023.11","url":null,"abstract":"<p><p>Glomerular filtration rate (GFR) is estimated from equations based on serum or plasma concentrations of endogenous markers (creatinine and/or cystatin C), and demographic data (age, sex, ± ethnicity). These equations are accurate at the population level, but often inaccurate at the individual level. The creatinine-based Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation published in 2009 (CKD-EPIcr-2009), and the CKD-EPI equation published in 2012 based on creatinine and cystatin C, were recalibrated in 2021 to remove their dedicated race correction factors for black American subjects. All creatinine-based CKD-EPI equations overestimate true GFR in subjects younger than 30 years. The Full Age Spectrum (FAS) equation, applicable across the entire age spectrum (pediatrics to old age), solved this problem, but remained suboptimal at low GFR values. The European Kidney Function Consortium (EKFC) equation published in 2021 was an improvement of the FAS equation, which also includes the Q factor (median creatinine in the general population). EKFC is applicable across the age spectrum and is efficient at low and normal GFR values. The new creatinine-based CKD-EPI equation (CKD-EPIcr-2021) underestimates GFR in Black Americans and overestimates it in non-Black Americans. In European and African subjects, CKD-EPIcr-2021 overestimates true GFR and should not be adopted. The EKFC equation, which performs well in this population, also performs well in European Black subjects and in African subjects, provided dedicated Q factors are used.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-10"},"PeriodicalIF":0.7,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10846512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimation of glomerular filtration rate in children: interest of FAS formula 儿童肾小球滤过率的评估:FAS公式的意义
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-03-02 DOI: 10.1684/ndt.2023.12
Pauline Ratouit, Jérôme Harambat, Annie M Bérard, Geneviève Lacape

The recommended equation to estimate the value of glomerular filtration rate (eGFR) among children is Schwartz equation updated in 2009. However, it is few frequently used because involves height, a factor rarely documented for laboratories, especially hospital laboratories. The FAS (Full Aged Spectrum) formula developed by a European group, allows to get away from this factor. We compared CKD-EPI (Chronic Kidney Disease-EPIdemiology collaboration) and FAS formulas to Schwartz equation to estimate GFR in children. We realized a retrospective study included 1.668 children between 2 and 14 years old, whose serum creatinine had been measured during their hospitalization stay. We showed that FAS formula is correlated to Schwartz (r = 0.88), with a mean underestimation of eGFR at 6.2% versus CKD-EPI which has a correlation coefficient equal to 0.45 and overestimates eGFR to approximatively 42.0% compared to Schwartz formula. Furthermore, concordance at 30% is 99% with FAS whereas it’s only 35% with CKD-EPI. Thus, we recommend using the FAS formula to estimate GFR in children between 2 and 14 years old when their height is not available.

估计儿童肾小球滤过率(eGFR)值的推荐公式是2009年更新的Schwartz公式。然而,它很少经常使用,因为涉及到身高,一个因素很少记录实验室,特别是医院实验室。由一个欧洲小组开发的FAS(全年龄谱)公式可以摆脱这个因素。我们比较了CKD-EPI(慢性肾脏疾病-流行病学合作)和FAS公式与Schwartz方程来估计儿童GFR。我们实现了一项回顾性研究,包括1668名2至14岁的儿童,他们在住院期间测量了血清肌酐。我们发现FAS公式与Schwartz相关(r = 0.88),与CKD-EPI相比,平均低估eGFR为6.2%,而CKD-EPI的相关系数为0.45,与Schwartz公式相比,高估eGFR约为42.0%。此外,FAS患者的一致性为99%,而CKD-EPI患者的一致性仅为35%。因此,我们建议使用FAS公式来估计2至14岁儿童的GFR,当他们的身高无法获得时。
{"title":"Estimation of glomerular filtration rate in children: interest of FAS formula","authors":"Pauline Ratouit,&nbsp;Jérôme Harambat,&nbsp;Annie M Bérard,&nbsp;Geneviève Lacape","doi":"10.1684/ndt.2023.12","DOIUrl":"https://doi.org/10.1684/ndt.2023.12","url":null,"abstract":"<p><p>The recommended equation to estimate the value of glomerular filtration rate (eGFR) among children is Schwartz equation updated in 2009. However, it is few frequently used because involves height, a factor rarely documented for laboratories, especially hospital laboratories. The FAS (Full Aged Spectrum) formula developed by a European group, allows to get away from this factor. We compared CKD-EPI (Chronic Kidney Disease-EPIdemiology collaboration) and FAS formulas to Schwartz equation to estimate GFR in children. We realized a retrospective study included 1.668 children between 2 and 14 years old, whose serum creatinine had been measured during their hospitalization stay. We showed that FAS formula is correlated to Schwartz (r = 0.88), with a mean underestimation of eGFR at 6.2% versus CKD-EPI which has a correlation coefficient equal to 0.45 and overestimates eGFR to approximatively 42.0% compared to Schwartz formula. Furthermore, concordance at 30% is 99% with FAS whereas it’s only 35% with CKD-EPI. Thus, we recommend using the FAS formula to estimate GFR in children between 2 and 14 years old when their height is not available.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-9"},"PeriodicalIF":0.7,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10839288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency hemodialysis in the Joseph Raseta Befelatanana hospital, Antananarivo, Madagascar 在马达加斯加塔那那利佛的Joseph Raseta Befelatanana医院进行紧急血液透析
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-02-28 DOI: 10.1684/ndt.2023.5
Rova Malala Fandresena Randrianarisoa, Eliane Mikkelsen Ranivoharisoa, Ainasalohimanana Randrianarisoa, Benja Ramilitiana, Willy Franck Harilalaina Randriamarotia

Introduction: Initiation of emergency dialysis is a critical situation responsible for high morbidity and mortality. This study describes the characteristics of emergency hemodialysis patients in a hospital in Madagascar.

Patients and methods: It is a descriptive study over a period of 7 months, from September 1, 2018 to March 31, 2019, on emergency hemodialysis patients in the hemodialysis department of the University Hospital of Joseph Raseta Befelatanana, Antananarivo. Emergency hemodialysis was defined as dialysis performed immediately or within the first 48 hours of hospitalisation in a life-threatening situation.

Results: Among 124 haemodialysis patients, 52 patients (41.93%) had started dialysis as an emergency. The mean age of patients was 50.5 years and the sex ratio (male/female) was 1.08. Hypertension (51.92%) and diabetes (34.61%) were the main comorbidities. Chronic kidney disease was found in 82.7%. The majority of patients were unprepared and had initiated dialysis with a central venous catheter. The most frequent indication was Kussmaul's breathing (32.6%) followed by anuria (28.84%). The mortality rate was 23.08% and the prognosis was influenced by their condition on arrival.

Conclusion: The predominance of chronic kidney disease and the absence of a permanent vascular approach can be explained by the late referral to nephrologists of patients with chronic kidney disease. Efforts need to be made to increase the proportion of scheduled dialysis patients with a permanent approach.

导读:紧急透析的开始是造成高发病率和死亡率的关键情况。本研究描述了马达加斯加一家医院急诊血液透析患者的特点。患者和方法:这是一项描述性研究,为期7个月,从2018年9月1日至2019年3月31日,对塔那那利佛约瑟夫·拉塞塔·贝费拉塔纳纳大学医院血液透析科的紧急血液透析患者。紧急血液透析被定义为在有生命危险的情况下立即或在住院后48小时内进行的透析。结果:124例血液透析患者中,52例(41.93%)为急诊透析。患者平均年龄50.5岁,男女性别比1.08。高血压(51.92%)和糖尿病(34.61%)为主要合并症。慢性肾脏疾病占82.7%。大多数患者没有准备好,并开始透析中心静脉导管。最常见的指征是Kussmaul呼吸(32.6%),其次是无尿(28.84%)。病死率为23.08%,预后受入院时病情影响。结论:慢性肾脏疾病的优势和永久血管入路的缺乏可以解释慢性肾脏疾病患者转诊较晚。需要作出努力,增加采用永久性方法的计划透析患者的比例。
{"title":"Emergency hemodialysis in the Joseph Raseta Befelatanana hospital, Antananarivo, Madagascar","authors":"Rova Malala Fandresena Randrianarisoa,&nbsp;Eliane Mikkelsen Ranivoharisoa,&nbsp;Ainasalohimanana Randrianarisoa,&nbsp;Benja Ramilitiana,&nbsp;Willy Franck Harilalaina Randriamarotia","doi":"10.1684/ndt.2023.5","DOIUrl":"https://doi.org/10.1684/ndt.2023.5","url":null,"abstract":"<p><strong>Introduction: </strong>Initiation of emergency dialysis is a critical situation responsible for high morbidity and mortality. This study describes the characteristics of emergency hemodialysis patients in a hospital in Madagascar.</p><p><strong>Patients and methods: </strong>It is a descriptive study over a period of 7 months, from September 1, 2018 to March 31, 2019, on emergency hemodialysis patients in the hemodialysis department of the University Hospital of Joseph Raseta Befelatanana, Antananarivo. Emergency hemodialysis was defined as dialysis performed immediately or within the first 48 hours of hospitalisation in a life-threatening situation.</p><p><strong>Results: </strong>Among 124 haemodialysis patients, 52 patients (41.93%) had started dialysis as an emergency. The mean age of patients was 50.5 years and the sex ratio (male/female) was 1.08. Hypertension (51.92%) and diabetes (34.61%) were the main comorbidities. Chronic kidney disease was found in 82.7%. The majority of patients were unprepared and had initiated dialysis with a central venous catheter. The most frequent indication was Kussmaul's breathing (32.6%) followed by anuria (28.84%). The mortality rate was 23.08% and the prognosis was influenced by their condition on arrival.</p><p><strong>Conclusion: </strong>The predominance of chronic kidney disease and the absence of a permanent vascular approach can be explained by the late referral to nephrologists of patients with chronic kidney disease. Efforts need to be made to increase the proportion of scheduled dialysis patients with a permanent approach.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-7"},"PeriodicalIF":0.7,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10846505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2022-2026 Transplantation Plan: objectives and priorities for a new development of kidney transplantation 2022-2026年移植计划:肾移植新发展的目标和优先事项
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-02-28 DOI: 10.1684/ndt.2023.3
Maryvonne Hourmant, Philippe Gatault, Dany Anglicheau, Bruno Moulin, Sébastien Canet, Valérie Chatelet, Camille Dubart, Alexandre Hertig, Betoul Schvartz, Christophe Mariat

The 2022-2026 Transplantation Plan has been launched by the French government to stimulate the activities of organ harvesting and transplantation, after the failure of the previous one. It has been designed by the Biomedicine Agency in collaboration with learning societies, including the SFNDT, and patient associations. The plan is original in its objectives, its regional organization with its driving by the Regional Health Agencies, the involvement of advanced practice nurses and its funding. The ambition is to transplant every transplantable patient. The increase in the number of kidney transplantations, more of all from a living donor, requires the active participation of all the nephrologists, who are the first in delivering information to the patients and their family on advanced chronic kidney disease treatment and living donation.

在之前的移植计划失败后,法国政府启动了2022-2026移植计划,以刺激器官摘取和移植活动。它是由生物医药机构与包括SFNDT在内的学习团体和患者协会合作设计的。该计划在目标、区域组织(由区域卫生机构推动)、高级执业护士的参与以及资金方面都是独创的。我们的目标是移植每一个可以移植的病人。肾脏移植数量的增加,更多的是来自活体供体,需要所有肾脏学家的积极参与,他们是第一个向患者及其家属提供晚期慢性肾脏疾病治疗和活体捐赠信息的人。
{"title":"The 2022-2026 Transplantation Plan: objectives and priorities for a new development of kidney transplantation","authors":"Maryvonne Hourmant,&nbsp;Philippe Gatault,&nbsp;Dany Anglicheau,&nbsp;Bruno Moulin,&nbsp;Sébastien Canet,&nbsp;Valérie Chatelet,&nbsp;Camille Dubart,&nbsp;Alexandre Hertig,&nbsp;Betoul Schvartz,&nbsp;Christophe Mariat","doi":"10.1684/ndt.2023.3","DOIUrl":"https://doi.org/10.1684/ndt.2023.3","url":null,"abstract":"<p><p>The 2022-2026 Transplantation Plan has been launched by the French government to stimulate the activities of organ harvesting and transplantation, after the failure of the previous one. It has been designed by the Biomedicine Agency in collaboration with learning societies, including the SFNDT, and patient associations. The plan is original in its objectives, its regional organization with its driving by the Regional Health Agencies, the involvement of advanced practice nurses and its funding. The ambition is to transplant every transplantable patient. The increase in the number of kidney transplantations, more of all from a living donor, requires the active participation of all the nephrologists, who are the first in delivering information to the patients and their family on advanced chronic kidney disease treatment and living donation.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-5"},"PeriodicalIF":0.7,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10846508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New year, new publisher, new format for Néphrologie & Thérapeutique 新的一年,新的出版商,新的格式的nsamaprology & thsamapeutique
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-02-28 DOI: 10.1684/ndt.2023.8
Luc Frimat, François Vrtovsnik, Justine Bacchetta, Cécile Vigneau, Valérie Moal
{"title":"New year, new publisher, new format for Néphrologie & Thérapeutique","authors":"Luc Frimat,&nbsp;François Vrtovsnik,&nbsp;Justine Bacchetta,&nbsp;Cécile Vigneau,&nbsp;Valérie Moal","doi":"10.1684/ndt.2023.8","DOIUrl":"https://doi.org/10.1684/ndt.2023.8","url":null,"abstract":"","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-2"},"PeriodicalIF":0.7,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10846509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of chronic kidney disease stage V treated in southeastern Algeria: prospective study from 2016 to 2018 阿尔及利亚东南部慢性肾脏疾病V期治疗的流行病学:2016 - 2018年的前瞻性研究
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-02-28 DOI: 10.1684/ndt.2023.4
Nassim Meguellati, Tahar Rayane, Younes Boulahia, Messaoud Saidani, Ahsène Atik, Abderrahmane Saidi, Mohamed Tayeb Saadi, Zoheir Laib, Mustapha Hanba, Mebarek Kellil, Nacereddine Regaiguia, Mahmoud Bousakhria, Djahid Bendjeddou

Introduction: Chronic kidney disease stage V, by its incidence and its prevalence which are constantly increasing in the world and in Algeria, the morbidity and mortality it generates, the high cost of its treatment, represents a major public health issue. Our objective is to describe the epidemiology of stage V chronic kidney disease treated in south-eastern Algeria.

Patients and methods: In our regional, multicenter, prospective descriptive study, all patients with stage V chronic kidney disease, residing and treated in south-eastern Algeria between September 1, 2016, and December 31, 2017, were included and followed up until December 31, 2018.

Results: Stage V chronic kidney disease is a frequent pathology in the region: 1934 patients were included. It mainly affects young people: the average age of patients was 50.17 ± 16.98 years, with a male predominance of 59.10%. High blood pressure and diabetes are the two main causes. The start of dialysis on a temporary catheter represents 81.5% of cases, the initial management requires emergency dialysis in 91.2% of cases. In total, 97.1% of chronic hemodialysis patients use an arteriovenous fistula as a permanent vascular access.

Conclusion: Our study population is younger than that of developed countries and has fewer comorbidities and disabilities but lower survival and high mortality. The developing national chronic kidney disease stage V registry is becoming an absolute necessity. It will allow to have a better knowledge of its epidemiology and the needs of its care in each region. It can contribute to improving the prevention and management of this disease.

导言:慢性肾脏疾病第五期的发病率和流行率在世界和阿尔及利亚不断增加,它造成的发病率和死亡率以及治疗费用高,是一个重大的公共卫生问题。我们的目标是描述在阿尔及利亚东南部治疗的V期慢性肾脏疾病的流行病学。患者和方法:在我们的区域性、多中心、前瞻性描述性研究中,纳入了2016年9月1日至2017年12月31日期间在阿尔及利亚东南部居住和治疗的所有V期慢性肾脏疾病患者,并随访至2018年12月31日。结果:V期慢性肾脏疾病是该地区常见的病理:纳入了1934例患者。以年轻人为主,患者平均年龄50.17±16.98岁,男性占59.10%。高血压和糖尿病是两个主要原因。81.5%的病例以临时导尿管开始透析,91.2%的病例需要紧急透析。总的来说,97.1%的慢性血液透析患者使用动静脉瘘作为永久性血管通路。结论:我们的研究人群比发达国家年轻,合并症和残疾较少,但生存率较低,死亡率较高。发展中的国家慢性肾脏疾病V期登记正成为绝对必要的。它将使我们能够更好地了解其流行病学以及每个区域对其护理的需求。它有助于改善这种疾病的预防和管理。
{"title":"Epidemiology of chronic kidney disease stage V treated in southeastern Algeria: prospective study from 2016 to 2018","authors":"Nassim Meguellati,&nbsp;Tahar Rayane,&nbsp;Younes Boulahia,&nbsp;Messaoud Saidani,&nbsp;Ahsène Atik,&nbsp;Abderrahmane Saidi,&nbsp;Mohamed Tayeb Saadi,&nbsp;Zoheir Laib,&nbsp;Mustapha Hanba,&nbsp;Mebarek Kellil,&nbsp;Nacereddine Regaiguia,&nbsp;Mahmoud Bousakhria,&nbsp;Djahid Bendjeddou","doi":"10.1684/ndt.2023.4","DOIUrl":"https://doi.org/10.1684/ndt.2023.4","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic kidney disease stage V, by its incidence and its prevalence which are constantly increasing in the world and in Algeria, the morbidity and mortality it generates, the high cost of its treatment, represents a major public health issue. Our objective is to describe the epidemiology of stage V chronic kidney disease treated in south-eastern Algeria.</p><p><strong>Patients and methods: </strong>In our regional, multicenter, prospective descriptive study, all patients with stage V chronic kidney disease, residing and treated in south-eastern Algeria between September 1, 2016, and December 31, 2017, were included and followed up until December 31, 2018.</p><p><strong>Results: </strong>Stage V chronic kidney disease is a frequent pathology in the region: 1934 patients were included. It mainly affects young people: the average age of patients was 50.17 ± 16.98 years, with a male predominance of 59.10%. High blood pressure and diabetes are the two main causes. The start of dialysis on a temporary catheter represents 81.5% of cases, the initial management requires emergency dialysis in 91.2% of cases. In total, 97.1% of chronic hemodialysis patients use an arteriovenous fistula as a permanent vascular access.</p><p><strong>Conclusion: </strong>Our study population is younger than that of developed countries and has fewer comorbidities and disabilities but lower survival and high mortality. The developing national chronic kidney disease stage V registry is becoming an absolute necessity. It will allow to have a better knowledge of its epidemiology and the needs of its care in each region. It can contribute to improving the prevention and management of this disease.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-13"},"PeriodicalIF":0.7,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10855723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Green Nephrology Group of the SFNDT: initial reflections SFNDT绿色肾脏病组:初步反思
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2023-02-28 DOI: 10.1684/ndt.2023.1
Charles Chazot, Hafsah Hachad, Pierre Filipozzi, Cécile Legallais, Perrine Jullien, Fabrice Huré, Karim Dardim, Catherine Lasseur, Hubert Metayer, Didier Aguilera, Agnès Caillette-Beaudoin, Christophe Mariat, Maryvonne Hourmant

Preserving the environment is becoming a universal priority. Human activities must be redesigned to best adapt them to available resources and to reduce their deleterious impact on the planet. The Green Nephrology Group of the “Société française de néphrologie, dialyse et transplantation” (SFNDT) has started a reflection on these issues, in particular on dialysis, a vital treatment but with high carbon production, associated with high water consumption. The data available on these points are presented such as, among others, the collection of indicators and action plans, the recycling of waste from water treatment, the reduction of dialysate flow, the reuse and regeneration of spent dialysate as well as calculations of carbon emission by dialysis activity. Architectural experiences are reported as well as the regulatory constraints applying to manufacturers and organizations in the sector. Potential solutions require the mobilization of all stakeholders, ranging from patients to health authorities, including caregivers, pharmacists, technicians, nephrologists and facility managers. They will be formalized very soon in a guide being prepared by the SFNDT Green Nephrology Group.

保护环境正成为一个普遍的优先事项。人类活动必须重新设计,以使其最好地适应现有资源,并减少其对地球的有害影响。“社会医疗、医疗、透析和移植”(SFNDT)的绿色肾脏学小组已经开始对这些问题进行反思,特别是透析,这是一种至关重要的治疗方法,但碳排放量高,耗水量大。介绍了这些方面的现有数据,例如指标和行动计划的收集、水处理废物的回收、透析液流量的减少、废透析液的再利用和再生以及透析活动碳排放的计算。报告了体系结构经验以及应用于该部门的制造商和组织的法规约束。潜在的解决办法需要动员从患者到卫生当局的所有利益攸关方,包括护理人员、药剂师、技术人员、肾病学家和设施管理人员。他们将很快在SFNDT绿色肾脏学小组准备的指南中正式确定。
{"title":"The Green Nephrology Group of the SFNDT: initial reflections","authors":"Charles Chazot,&nbsp;Hafsah Hachad,&nbsp;Pierre Filipozzi,&nbsp;Cécile Legallais,&nbsp;Perrine Jullien,&nbsp;Fabrice Huré,&nbsp;Karim Dardim,&nbsp;Catherine Lasseur,&nbsp;Hubert Metayer,&nbsp;Didier Aguilera,&nbsp;Agnès Caillette-Beaudoin,&nbsp;Christophe Mariat,&nbsp;Maryvonne Hourmant","doi":"10.1684/ndt.2023.1","DOIUrl":"https://doi.org/10.1684/ndt.2023.1","url":null,"abstract":"<p><p>Preserving the environment is becoming a universal priority. Human activities must be redesigned to best adapt them to available resources and to reduce their deleterious impact on the planet. The Green Nephrology Group of the “Société française de néphrologie, dialyse et transplantation” (SFNDT) has started a reflection on these issues, in particular on dialysis, a vital treatment but with high carbon production, associated with high water consumption. The data available on these points are presented such as, among others, the collection of indicators and action plans, the recycling of waste from water treatment, the reduction of dialysate flow, the reuse and regeneration of spent dialysate as well as calculations of carbon emission by dialysis activity. Architectural experiences are reported as well as the regulatory constraints applying to manufacturers and organizations in the sector. Potential solutions require the mobilization of all stakeholders, ranging from patients to health authorities, including caregivers, pharmacists, technicians, nephrologists and facility managers. They will be formalized very soon in a guide being prepared by the SFNDT Green Nephrology Group.</p>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"19 1","pages":"1-11"},"PeriodicalIF":0.7,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10855722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Place de l’avacopan dans le traitement de la vascularite associée aux ANCA What role for avacopan in the treatment of ANCA-associated vasculitis? avacopan在髋关节相关血管炎治疗中的作用avacopan在髋关节相关血管炎治疗中的作用是什么?
IF 0.7 4区 医学 Q3 Medicine Pub Date : 2022-12-01 DOI: 10.1016/S1769-7255(22)00647-2
Alexandre Karras

Des données expérimentales récentes ont révélé que le complément, et plus particulièrement le composé C5a, joue un rôle majeur dans la physiopathologie de la vascularite à ANCA. Le développement d’un inhibiteur oral du récepteur du C5a, l’avacopan, a permis de tester cette nouvelle piste thérapeutique, initialement dans un modèle murin de la maladie, puis chez l’homme, au cours d’un essai thérapeutique préliminaire de phase 2, avec des résultats encourageants. Dans l’étude internationale de phase 3, publiée en 2021, les auteurs ont démontré que l’avacopan pouvait remplacer efficacement les corticoïdes au cours du traitement d’induction de la vascularite à ANCA, en association avec un immunosuppresseur comme le rituximab ou le cyclophosphamide. L’adjonction de cet immunosuppresseur de nouvelle génération ne majore pas le risque infectieux, mais permet d’amplifier la récupération de la fonction rénale lors du traitement initial de la vascularite rénale. Ces résultats ont conduit à l’obtention d’une AMM pour l’avacopan en 2022, apportant désormais une nouvelle option thérapeutique dans la vascularite à ANCA.

© 2022 Publié par Elsevier Masson SAS au nom de Société francophone de néphrologie, dialyse et transplantation.

Recent experimental data have revealed the complement, and more specifically the C5a compound, plays a major role in the pathophysiology of ANCA associated vasculitis (AAV). The development of avacopan, an oral inhibitor of C5a receptor, has allowed to test the blockade of this immunological pathway, initially in a murine animal model of the disease, followed by a preliminary, phase 2 therapeutic trial in human disease, with promising results. An international phase 3 trial published in 2021 demonstrated that avacopan can be used instead of corticosteroids for the induction therapy of AAV, in association with an immunosuppressive drug such as cyclophosphamide or rituximab. The adjunction of this new-generation immunosuppressive drug does not increase the infectious risk, but seems to amplify the improvement of renal function during the initial treatment of renal vasculitis. These results have led to the recent registration of avacopan, opening new therapeutic options in AAV.

© 2022 Published by Elsevier Masson SAS on behalf of Société francophone de néphrologie, dialyse et transplantation.

最近的实验数据表明,补体,特别是C5a化合物,在髋关节血管炎的病理生理学中起着重要作用。一种口服C5a受体抑制剂avacopan的开发使这种新的治疗途径得以测试,首先在该疾病的小鼠模型中,然后在初步的2期治疗试验中在人类中,取得了令人鼓舞的结果。在2021年发表的国际3期研究中,作者证明阿瓦科潘与利妥昔单抗或环磷酰胺等免疫抑制剂联合治疗髋关节血管炎时,可以有效替代皮质类固醇。新一代免疫抑制剂的加入不会增加感染的风险,但有助于在肾血管炎的初始治疗期间增强肾功能的恢复。这些结果导致avacopan在2022年获得ma,现在为ANCA血管炎提供了一种新的治疗选择。©2022由爱思唯尔·马森SAS代表法国肾病、透析和移植协会出版。数据have钦the Recent实验计划,and more the C5a复合物,具体什么a major in the pathophysiology of安卡associated分泌物的作用(AAV)。阿瓦科潘(avacopan)是一种C5a受体的oral抑制剂,它的开发使该免疫途径的blockade成为可能,最初是在疾病的小鼠动物模型中,随后是在人类疾病的初步2期治疗试验,结果很有希望。in An international第三阶段试验吊至2021年地表水that avacopan can be used corticosteroids for the诱导治疗而不是向AAV, in with An immunosuppressive drug such as环磷酰胺rituximab黄金协会。increase The adjunction of this new-generation immunosuppressive drug does not The风险,但是我想,amplify during The初次治疗of The improvement of renal功能renal分泌物。这些结果导致了avacopan最近的注册,为avacopan提供了新的治疗选择。©2022由爱思唯尔·马森SAS出版,由法国肾病、透析和移植学会出版。
{"title":"Place de l’avacopan dans le traitement de la vascularite associée aux ANCA What role for avacopan in the treatment of ANCA-associated vasculitis?","authors":"Alexandre Karras","doi":"10.1016/S1769-7255(22)00647-2","DOIUrl":"10.1016/S1769-7255(22)00647-2","url":null,"abstract":"<div><p>Des données expérimentales récentes ont révélé que le complément, et plus particulièrement le composé C5a, joue un rôle majeur dans la physiopathologie de la vascularite à ANCA. Le développement d’un inhibiteur oral du récepteur du C5a, l’avacopan, a permis de tester cette nouvelle piste thérapeutique, initialement dans un modèle murin de la maladie, puis chez l’homme, au cours d’un essai thérapeutique préliminaire de phase 2, avec des résultats encourageants. Dans l’étude internationale de phase 3, publiée en 2021, les auteurs ont démontré que l’avacopan pouvait remplacer efficacement les corticoïdes au cours du traitement d’induction de la vascularite à ANCA, en association avec un immunosuppresseur comme le rituximab ou le cyclophosphamide. L’adjonction de cet immunosuppresseur de nouvelle génération ne majore pas le risque infectieux, mais permet d’amplifier la récupération de la fonction rénale lors du traitement initial de la vascularite rénale. Ces résultats ont conduit à l’obtention d’une AMM pour l’avacopan en 2022, apportant désormais une nouvelle option thérapeutique dans la vascularite à ANCA.</p><p>© 2022 Publié par Elsevier Masson SAS au nom de Société francophone de néphrologie, dialyse et transplantation.</p></div><div><p>Recent experimental data have revealed the complement, and more specifically the C5a compound, plays a major role in the pathophysiology of ANCA associated vasculitis (AAV). The development of avacopan, an oral inhibitor of C5a receptor, has allowed to test the blockade of this immunological pathway, initially in a murine animal model of the disease, followed by a preliminary, phase 2 therapeutic trial in human disease, with promising results. An international phase 3 trial published in 2021 demonstrated that avacopan can be used instead of corticosteroids for the induction therapy of AAV, in association with an immunosuppressive drug such as cyclophosphamide or rituximab. The adjunction of this new-generation immunosuppressive drug does not increase the infectious risk, but seems to amplify the improvement of renal function during the initial treatment of renal vasculitis. These results have led to the recent registration of avacopan, opening new therapeutic options in AAV.</p><p>© 2022 Published by Elsevier Masson SAS on behalf of Société francophone de néphrologie, dialyse et transplantation.</p></div>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"18 6","pages":"Pages 6S7-6S10"},"PeriodicalIF":0.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10815368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nephrologie & Therapeutique
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1